Modulation of SCD1 activity in hepatocyte cell lines: evaluation of genomic stability and proliferation

α-Tocopherol-13′-Carboxychromanol Induces Cell Cycle Arrest and Cell Death by Inhibiting the SREBP1-SCD1 Axis and Causing Imbalance in Lipid Desaturation

“…In support of our hypothesis, the direct inhibition of SCD1 mimicked the effects of α-T-13 -COOH caused by the down-regulation of Scd1 expression. Our findings are in line with several studies reporting the pro-apoptotic and anti-proliferative effects of CAY10566 in multiple cell lines in vitro and also in (tumor) tissues in vivo [37,[67][68][69][70].…”

Lipid alterations in chronic liver disease and liver cancer

“… 208 The FASN inhibitor orlistat has also displayed antitumor activity in vitro 279 , 280 and in murine models, along with the inhibitors C75, 281 triclosan 21 , 282 and EGCG 283 showing promise in vitro . The SCD inhibitor CAY10566 has also been successful in ameliorating HCC in vitro 224 , 284 and in vivo 285 and the DGAT inhibitor tussilagone reduced TG synthesis in vitro . 286 Interestingly, sorafenib, which is an inhibitor of tyrosine kinases in HCC, 287 targets liver cancer cells by acting on the SCD1 pathway in vitro 288 and in human liver tumours 289 and, in return, SCD inhibition sensitises the tumour to sorafenib treatment.…”

An integrated analysis of dysregulated SCD1 in human cancers and functional verification of miR-181a-5p/SCD1 axis in esophageal squamous cell carcinoma

“…In contrast to the results above, SCD1 blockade in SKOV3, a high grade serous ovarian cell line, was relatively insensitive to cell death, indicating that SKOV3 cells have less sensitivity to SCD1 in the cell-death mechanism than in other ovarian cancer cells. Recent work reported that SCD1 promotes tumor growth and invasion and protects tumor cells against apoptosis-related death in HCC, pancreas, and colorectal cancers 14 , 36 , 37 . In lung cancer, SCD1 induces the stemness characteristics by stabilization of YAP/TAZ proteins [38] .…”